CTC Clinical Trial Consultants AB

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Obesity4 trials
• Atopic dermatitis (eczema)3 trials
• Type 2 diabetes2 trials
• Alopecia areata1 trial
• Coeliac disease1 trial
• Depression1 trial
• Epilepsy1 trial
• Insomnia1 trial
• Type 1 diabetes1 trial

Phase

• Phase 37 trials
• Phase 13 trials
• Phase 1/21 trial
• Phase 21 trial

Status

• Active, not recruiting4 trials
• Completed3 trials
• Recruiting3 trials
• Not yet recruiting2 trials

Lead sponsor

• Sanofi3 trials
• Novo Nordisk A/S2 trials
• AbbVie1 trial
• Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.1 trial
• AstraZeneca1 trial
• and 4 more

Running trials

• Recruiting

  A double-blind, randomised, placebo-controlled first-in-human/Phase Ib trial to investigate safety, tolerability, pharmacokinetics, and preliminary efficacy of single and multiple doses of TIR-C 2% cutaneous emulsion in adults with mild to moderate atopic dermatitis

  2026-526343-35-00· Phase 1· Pharmability AB· Source

• Recruiting

  A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

  NCT07776509· Phase 3· AstraZeneca· Source

• Not yet recruiting

  A two-part, randomised, double-blind, placebo-controlled, parallel-group, 12 week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants.

  2026-525869-42-00· Phase 1/2· Pila Pharma AB· Source

• Recruiting

  A randomized, multiple ascending doses, clinical trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of CV-01 after double-blind, placebo-controlled multiple oral administrations for 2 weeks in healthy volunteers, and multiple oral administrations open-label for 2 weeks in a cohort of participants with drug resistant epilepsy

  2026-525478-21-00· Phase 1· Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.· Source

• Recruiting

  Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

  NCT07770841· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

  NCT07665879· Phase 1· Eli Lilly and Company· Source

• Active, not recruiting

  A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

  NCT06557772· Phase 2· Sanofi· Source

• Recruiting

  Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  NCT06559306· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

  NCT06012240· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Epilepsy1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Active, not recruiting

  A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06407934· Phase 3· Sanofi· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

  NCT06181435· Phase 3· Sanofi· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source